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Rethinking our approach to postpartum haemorrhage
and uterotonics
Andrew Weeks and James Neilson suggest that we have inappropriately generalised evidence
on the use of uterotonics from uncomplicated births to all births. They call for stronger focus on
women with complex births to reduce deaths from postpartum haemorrhage
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Postpartum haemorrhage (defined as a bleed >500 mL) is
estimated to affect 1-15% of vaginal births, depending on the
definition used, the method of assessing blood loss, the setting,
and the population studied. Risk factors include Asian ethnicity,
obesity, previous postpartum haemorrhage, multiple pregnancy,
anaemia, large baby, age over 40, induction of labour, prolonged
labour, placental abruption, and caesarean delivery.1
Although global mortality from postpartum haemorrhage is
falling, its incidence is increasing in high resource settings, the
reasons for which are unclear.2-4 Many of those who survive
have severe anaemia, renal failure, or psychological trauma,
and the offspring may have difficulties in breast feeding and
bonding.
Current best practice globally is for all pregnant women to
receive a uterotonic drug at the time of childbirth to prevent
postpartum haemorrhage. This recommendation has been in
place since the 1980s when randomised trials showed that
routine prophylaxis with oxytocin based uterotonic drugs
reduced the rate of postpartum haemorrhage.5 The assumption
that this would translate into fewer maternal deaths—based on
the understanding that atony was the most common cause of
haemorrhage related deaths—led to the promotion of active
management of the third stage of labour, which comprises a
prophylactic uterotonic drug, early cord clamping, and controlled
cord traction.
Here we discuss the problems with generalising data from
spontaneous vaginal (“normal”) births to complex births, and
call for a change in global strategy on postpartum haemorrhage.
Rationale for universal prophylaxis
Atonic uterus is the failure of the uterine muscle to contract
adequately to stop blood flow to the placental bed after
detachment of the placenta in the third stage of labour. The
reported rate of atonic uterus in women with postpartum
haemorrhage in high resource settings varies widely, from 30%
to 79%.4 6 This is partially because the diagnosis of atony is
often subjective and used in the absence of retained placental
tissue or obvious trauma.
Atony is also difficult to assess at the time of caesarean section,
when the assessment is made on palpation of uterine tone rather
than on vaginal blood loss, which is largely hidden under
surgical drapes. In practice the diagnosis is given in a wide range
of clinical situations, from a woman with a small bleed after
spontaneous vaginal birth to a woman bleeding heavily after
emergency caesarean for obstructed labour.
Uterotonic agents such as oxytocin, ergometrine, and
misoprostol stimulate uterine contractions, and numerous high
quality randomised controlled trials have shown that they reduce
the rate of postpartum haemorrhage when given
prophylactically.7 For example, a meta-analysis of oxytocin
prophylaxis trials shows an overall reduction in severe
postpartum haemorrhage (defined as >1000 mL) of 38%
compared with placebo (risk ratio 0.62, 95% confidence interval
0.44 to 0.87).8 Similarly, active management of labour as a
package reduces the rate of severe postpartum haemorrhage by
66% compared with physiological care (0.34, 0.14 to 0.87).7
For the treatment of postpartum haemorrhage, there are studies
that compare different oxytocics but understandably very few
trials with an arm that receives no treatment or placebo.
Observational studies suggest that widespread availability of
uterotonics for the management of postpartum haemorrhage
may reduce deaths.9 10 But there is little evidence of an effect
on maternal deaths from randomised trial data, at least for
misoprostol.11
Given that oxytocin and misoprostol are relatively free from
adverse effects, global evidence based efforts have focused on
promoting the use of uterotonics for all births.12 However, the
problem with generalising the available evidence to all births
is that trials tend to exclude women who have complicated
births, and yet they are the births most likely to end in maternal
death.
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Evidence based on uncomplicated births
Two landmark multicentre studies conducted in low resource
settings in 2005-08 puzzled researchers with their low rates of
large postpartum haemorrhages (defined as >1700 mL). These
bleeds were experienced by just eight of 9348 women (0.09%)
who had a vaginal birth without oxytocin prophylaxis,13 and 14
of 31 055 of those (0.05%) who did receive prophylaxis.14 This
compares to rates of around 0.5-1% for postpartum bleeds of
2000-2500 mL with prophylaxis in high resource populations
(table⇓).15
Similarly, a systematic review in 2013 found only eight deaths
in 36 283 women (0.02%) who participated in trials of
misoprostol prophylaxis in low and middle income countries.11
This is lower than the 0.1% of deaths due to postpartum
haemorrhage that would be expected, based on the assumption
that 27% of maternal deaths are due to postpartum
haemorrhage,16 in settings where the maternal mortality rates
are around 400 per 100 000 live births.
One likely contributor to such low rates is the difficulty of
recruiting patients to clinical trials of postpartum haemorrhage.
Logistical and consent difficulties mean that trials generally
only include low risk women with uncomplicated, spontaneous
vaginal births, in whom postpartum haemorrhage is relatively
uncommon. Consequently the trials exclude those who have
caesarean sections or instrumental births or who develop
intrapartum complications such as placental abruption or
dysfunctional labour.7 For example, only 10 of the 1881 women
in the Cochrane review of treatments for postpartum
haemorrhage had caesarean sections despite this being a major
risk factor for postpartum haemorrhage.9
This inclusion bias is a problem. Excessive blood loss is well
recognised to be far more common in women who have
complicated births.17-19 In data from Liverpool Women’s
Hospital, the 14% of women who had emergency caesarean
sections made up nearly 40% of postpartum haemorrhages of
>2000mL (fig 1⇓). Conversely, only 0.3% of the 28% of women
who were low risk and gave birth on the midwife led unit had
massive postpartum haemorrhages, representing 8% of all
massive postpartum haemorrhages in the hospital. And this is
despite an increasing number of women opting for a
physiological third stage of labour without the use of oxytocin
prophylaxis.
Uterotonics are not always effective
Uterotonics might not be as effective as we think for the
prevention of deaths frommajor postpartum haemorrhage. This
could be for two reasons—if atony isn’t the cause or if women
are not responsive to them. Although clinical trials demonstrate
the efficacy of uterotonics for reducing the rate of smaller,
largely atonic bleeds, these types of bleeds rarely lead to
maternal death. For example, in the inquiry into maternal deaths
in South Africa uterine atony accounted for just 6% of maternal
deaths from postpartum haemorrhage—even though many
women gave birth in areas with limited access to uterotonics.
Instead, most deaths occurred in women who had caesarean
sections (26%), uterine rupture (18%), abruptio placentae (16%),
or retained placenta (9%).20
Postpartum haemorrhage has several natural histories. Some
postpartum bleeds are very difficult to deal with clinically, for
example after a massive abruption and intrauterine death or
placenta praevia, and frequently require surgical intervention
before they cease. Women who give birth after prolonged
oxytocin use are also at risk of haemorrhage and seem to be less
responsive to oxytocin. Laboratory studies show that repeated
exposure to oxytocin reduces myometrial contractility,21 and
this is likely to reduce the efficacy of uterotonics in those who
have already received oxytocin. It is unsurprising therefore that
complicated and surgical births are over-represented in those
women having massive bleeds. By contrast, postpartum
haemorrhages after normal births and uncomplicated labours
are typically much easier to manage and have better
outcomes.13 14
Guidelines focus on normal births
Of 529 trial reports on techniques to prevent postpartum
haemorrhage in the Cochrane Pregnancy and Childbirth Trials
Register, 422 (80%) are on uterotonic drugs to prevent atony,
and most relate to normal births.
TheWHOguidelines reflect the underlying focus of randomised
controlled trials on normal births. In their 2012 guidelines, for
example, 10 of their 12 recommendations on the prevention of
postpartum bleeds are related to normal birth, and 11 of 20
recommendations on treatment are related to uterotonics or
treatment of the atonic uterus.12 The use of evidence based
medicine has led to the guidelines focusing on randomised
trials—and thus on women with low risk pregnancies.
This is in contrast to the non-evidence based recommendations
that arise from audits of maternal deaths, which focus on those
with the worst outcomes. For example the inquiry into maternal
deaths in South Africa examined 4867 maternal deaths in
2008-12. They made 10 recommendations on postpartum
haemorrhage: two on community detection of postpartum
haemorrhage and transport to health facilities, two on staff
training, three on effective assessment andmonitoring of women
with postpartum haemorrhage, two on clinical care for abruption
and labour induction, and just one on the use of uterotonics
(specifically, the use of stronger oxytocics in caesarean
section).20 In the United Kingdom the 2014 confidential inquiry
into maternal deaths made six recommendations on postpartum
haemorrhage: two relate to improving antenatal and intrapartum
care, and four to improving the quality of care of postpartum
haemorrhage in coagulopathy, monitoring, and early
hysterectomy.22
Call for clearer thinking on postpartum
haemorrhage
Women who have a postpartum haemorrhage exist on a
spectrum ranging from those with uncomplicated pregnancies
in whom major bleeds are rare to women with placental
abruption or praevia or second stage caesarean section in whom
major bleeds are common and difficult to control. Many women
exist between these extremes with minor risk factors, such as
instrumental deliveries and induced labour. The risk of
haemorrhage is raised in these women but if it occurs it is
usually easier to control. The number of low risk women whose
pregnancies have been uncomplicated up to the time of birth is
difficult to quantify, but is estimated at 43% in the UK.23 The
separation of women into groups according to their risk of
haemorrhage provides a useful model with wide implications
and potential benefits (fig 2⇓).
Firstly, it helps to reconcile the longstanding difference in views
of manymidwives and obstetricians. Advocates of physiological
management of the third stage of labour (including many
midwives) may be right not to focus on the dangers of
haemorrhage for women with low risk pregnancies,
uncomplicated labour, and minimal risk factors. Conversely,
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those who advocate active third stage management for all (a
policy largely driven by obstetricians) correctly see the high
risk of postpartum haemorrhage in women with complex births.
Both professions are correct with respect to the group of women
that they predominantly deal with. The only danger comes in
the belief that their own perception of risk applies to all births.
This can lead to an overly relaxed attitude towards high risk
women or the unnecessary medicalisation of low risk women.
Secondly, an understanding of the differences in postpartum
haemorrhage after normal and complicated births could help
explain temporal changes in its incidence. The underlying
reasons for the slowly rising rates of postpartum bleeds in well
resourced settings may be explained by rising rates of birth
intervention and risk factors. It also provides a hypothesis for
the major fall in deaths from postpartum haemorrhage in the
UK before the development of effective uterotonics in the
1930s.24 The arrival of interventions such as labour induction,
digital diagnosis of placenta praevia in theatre, and safe
caesarean section may have done much to reduce the rates of
bleeding from abruption, placenta praevia and obstructed labour,
respectively. All these interventions will have moved women
out of the highest risk group and given them a lower risk profile.
Thirdly, it shows how the recruitment of largely low risk women
to clinical trials has distorted the evidence base for the
prevention and treatment of postpartum haemorrhage. This has
led researchers and policy makers to unintentionally focus on
normal births. Future guidelines should broaden their scope and
give more weight to studies of postpartum bleeds after complex
births, even if they provide lower quality evidence. Data from
community based observational studies, audits, and confidential
inquiries may be essential.
Finally, this understanding has implications for global maternal
health. A focus on universal uterotonics may be effective for
the reduction of postnatal anaemia by reducing the average
blood loss at the time of birth. However, it is probably not the
most important or cost effective intervention globally to prevent
deaths from postpartum haemorrhage. This does not mean a
move away from the use of uterotonics for high risk births in
which atony may still be a contributing factor, but accepting
that they may be only a small part of the solution. It may prove
more important to provide good surgical facilities and technique,
haemodynamic support, and blood transfusion.
Further trials in those with complex risk factors will be crucial
to provide evidence to guide care for those with complex births.
The time has come to concentrate on those at the highest risk
both nationally and internationally.
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Key messages
Randomised controlled trials have shown uterotonics to be safe and effective for prophylaxis andmanagement of postpartum haemorrhage
But evidence on uterotonics was gathered predominantly from low risk women with normal births and may not apply to complex births,
where the risk of haemorrhage is higher
Because many guidelines are based on randomised trial evidence, they concentrate on normal births and largely ignore those most at
risk
In low resource settings efforts to reduce postpartum haemorrhage deaths may be better focused on those with complicated pregnancies
and births rather than on improving the access to routine uterotonics for lower risk women
Table
Table 1| Table Postpartum haemorrhage at Liverpool Women’s Hospital 2009-13 inclusive
Proportion of all postpartum
haemorrhage (%)
Risk of postpartum
haemorrhage (%)
Postpartum bleed ≥2000 ml
(n)
Total births (n)
8*0.33410 916Spontaneous vaginal birth (midwife led unit)
17.60.78612 997Induced or high risk normal birth (consultant
led unit)
20.61.6875586Operative vaginal birth
12.51.2534368Elective caesarean section
38.53.01635404Emergency caesarean section
1.142339 271Total
*38% of these were associated with need for manual removal of the placenta
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Figures
Fig 1 Births at Liverpool Women’s Hospital 2009-13. The graph on the left shows the types of birth among all women. The
graph on the right shows the types of birth for those who had bleeds >2000 mL
Fig 2 Spectrum of risk of postpartum haemorrhage
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